Targeting a Kynurenine-Driven Autocrine Loop to Block Triple-Negative Breast Cancer Metastasis
Project Number1F99CA212230-01
Former Number1K00CA212230-01
Contact PI/Project LeaderROGERS, THOMAS J
Awardee OrganizationUNIVERSITY OF COLORADO DENVER
Description
Abstract Text
Research and Related Other Project Information
7. Project Summary
The subtype of breast cancer known as triple negative breast cancer (TNBC) is unresponsive to endocrine or
HER2-targeted therapies. This subtype has the highest rate of recurrence and mortality in the first several
years after diagnosis, but to date there are no targeted therapeutic options to treat TNBC resistant to
chemotherapy. The ability of carcinoma cells to resist programmed cell death following detachment from a
basement membrane or primary tumor is known as anoikis resistance, and is thought to be critical for multiple
steps in the metastatic cascade. TNBC cells are more anoikis resistant than their less aggressive estrogen
receptor positive (ER+) counterparts, which may explain why ER+ disease becomes metastatic less often and
usually takes longer to recur. I made the novel discovery that multiple genes in the kynurenine pathway (KP)
of tryptophan catabolism are upregulated in anoikis resistant, anchorage independent TNBC cells. In summary,
upregulation of TDO2 in suspension promotes metastasis of TNBC via production of the intermediate
tryptophan metabolite, kynurenine, and subsequent activation of AhR5.
The goal of this proposal is to describe my novel graduate research and the steps to completion of my doctoral
studies and how they will facilitate successful transition to a postdoctoral position, leading to an independent
research position leading the field of cancer metabolism. Specifically in Aim 1, I will describe my graduate
research to-date focused on the KP promoting TNBC metastasis and its important clinical implications. In Aim
2, I describe research necessary to complete my dissertation focused on further characterizing tryptophan
catabolism in TNBC and downstream effectors of the KP that promote metastasis. Additionally, I explain how
completion of the proposed research will facilitate transition to a competitive postdoctoral position. Aim 3
describes how I will identify a mentor under which to obtain further training in cancer metabolism during my
postdoctoral studies and how to successfully transition to becoming a successful independent cancer
researcher. This proposal emphasizes a molecular understanding of metabolic signaling through the
kynurenine pathway that will provide the necessary preclinical framework to determine if therapeutic strategies
targeting the rate limiting enzyme in this pathway, TDO2, are feasible to reduce mortality of TNBC.
Furthermore, this proposal illustrates how the strengths of my graduate training in cancer cell biology and
molecular biology will complement a postdoctoral position emphasizing technical training in cancer metabolism
and support future translational cancer research. The completion of the proposed research will help the
National Cancer Institute fulfill their mission to support cancer research leading to novel therapeutic targets and
to encourage and retain enthusiastic graduate students training for a career as future independent cancer
biologists.
Public Health Relevance Statement
Research and Related Other Project Information
8. Project Narrative
Throughout my research career, my scientific interests have remained focused on understanding new
molecular mechanisms that promote tumorigenesis and novel therapeutic approaches to target these
processes. The role of oncometabolites, or metabolites that can directly contribute to tumorigenesis, has
become my main focus for my graduate research. Given the technical advancement in quantitatively
measuring metabolic flux and new metabolic imaging modalities, identifying and exploiting a tumor’s metabolic
tendencies is scientifically motivating for my goal of becoming a leader in the field of cancer metabolism.
No Sub Projects information available for 1F99CA212230-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1F99CA212230-01
Patents
No Patents information available for 1F99CA212230-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1F99CA212230-01
Clinical Studies
No Clinical Studies information available for 1F99CA212230-01
News and More
Related News Releases
No news release information available for 1F99CA212230-01
History
No Historical information available for 1F99CA212230-01
Similar Projects
No Similar Projects information available for 1F99CA212230-01